Background: Dyskinesia is one of the major complications of longterm dopaminergic treatment of Parkinson's disease (PD), and deep brain stimulation may be the only satisfactory treatment for it. This study aims to search if there is any therapeutic effect of repetitive transcranial magnetic stimulation (rTMS) for levodopa-induced dyskinesia (LID) in PD patients.Methods: This study was conducted in Mansoura International Specialized Hospital in 43 complicated idiopathic PD patients. The patients with LID were divided into two groups matched in age, sex, duration and stage of the disease. Dyskinesia was detected by the Unified PD Rating Scale section IV. The patients of the study group (20 patients) received active rTMS, 5 Hz was applied bilaterally over the motor hand and leg areas of the cortex, in 20 trains, and each train is formed of 100 pulses, with 20-s inter-train interval. Ten sessions were administered once per day for 10 successive days for each patient. The patients of the control group (20 patients) received sham rTMS.Results: After rTMS, there was significant improvement in LID in the study group (P < 0.001), while there was no improvement in the control one (P = 0.585). As regards to the LID clinical presentations, there was no significant difference between the two groups according to dyskinesia duration (P = 0.246), disability (P = 0.425) and early morning dystonia (P = 0.059), while there was significant improvement of painful dyskinesia in the study group (P = 0.046).
Conclusions:The rTMS may have an additional therapeutic benefit for LID. Further studies may put the best rTMS parameters to establish more prominent and longer-lasting clinical effects.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.